Emerging genetic biomarkers in lung adenocarcinoma

Barbar, Jawad; Armach, Maria; Hodroj, Mohammad Hassan; Assi, Sahar; Nakib, Clara El; Chamseddine, Nabil; Assi, Hazem

doi:10.1177/20503121221132352

Cited by 2 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that NCKAP1 may be a useful prognostic biomarker (18). Comprehensive genomic pro ling has identi ed many genomic variants as signi cant cancer biomarkers that might lead to the development of major clinical trials (19). NCKAP1 mutations were found to be most prevalent in UCEC, followed by SKCM, BLCA, STAD, and COAD.…”

Section: Discussionmentioning

confidence: 99%

Disulfidptosis-related NCK associated protein 1 as a potential biomarker for multiple tumor types: A pan-cancer analysis based on public databases

Cao

Hong

Shen

et al. 2023

Preprint

View full text Add to dashboard Cite

In the past decade, a number of cancer types have been reported to be associated with NCKAP1 encoded as a component of the WASF regulatory complex (WRC) and a poor prognosis. A study of the role of NCKAP1 across various types of tumors was conducted using data from The Cancer Genome Atlas (TCGA). There was an alteration in NCKAP1 expression in most tumor types when compared to corresponding non-tumor tissues. Survival analysis revealed that NCKAP1 overexpression was associated with poor OS and DFS only in kidney renal clear cell carcinoma (KIRC), and upregulated NCKAP1 expression was also significantly associated with the advanced cancer stage suggesting malignant progression in KIRC based on TCGA datasets using GEPIA2; Meanwhile, IHC staining showed NCKAP1 levels of KIRC tissues were significantly lower than normal tissues from HPA database. Following that, NCKAP1 alteration was associated with poor prognosis in cervical squamous cell carcinoma (CSCC) and lung adenocarcinoma (LUAD) patients in terms of PFS analyzed by cBioPortal. As a result, a positive correlation was observed between NCKAP1 expression and cancer-associated fibroblast infiltration in ACC, BRCA, CESC, LGG, and STAD. According to Gene Ontology analysis, NCKAP1 encodes a gene that regulates the actin cytoskeleton function. It was demonstrated from the protein interaction network that NCKAP1 interacts physically with CYFIP1, ABI2, WASF2 and BRK1, which have been well-characterized as actin cytoskeleton cycle regulators and cell disulfidptosis. There was a significant correlation between NCKAP1 expression and tumor prognosis in this multi-tumor study.

show abstract

Section: Discussionmentioning

confidence: 99%

Disulfidptosis-related NCK associated protein 1 as a potential biomarker for multiple tumor types: A pan-cancer analysis based on public databases

Cao

Hong

Shen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Thereinto, more than 50% of NSCLC patients are classified as lung adenocarcinoma (LUAD) ( 2 , 3 ). Although drugs targeting driver genes of LUAD have improved clinical treatment, LUAD patients inevitably develop drug resistance after treatment with these targeted drugs ( 4 ). With the development of the immune check-point inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), immunotherapy has revolutionized LUAD treatment in the recent decade and provided new approaches to improve the survival of LUAD patients ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) has become one of the most lethal cancers, for which the recurrence and survival rates remain unfavorable. The tumor necrosis factor (TNF) family is involved in tumorigenesis and tumor progression. Various long non-coding RNAs (lncRNAs) play important roles by mediating the TNF family in cancer. Therefore, this study aimed to construct a TNF-related lncRNA signature to predict prognosis and immunotherapy response in LUAD. Methods:The expression of TNF family members and their related lncRNAs in a total of 500 enrolled LUAD patients was collected from The Cancer Genome Atlas (TCGA). Univariate Cox and the least absolute shrinkage and selection operator (LASSO)-Cox analysis was used to construct a TNF family-related lncRNA prognostic signature. Kaplan-Meier (KM) survival analysis was used to evaluate survival status. The time-dependent area under the receiver operating characteristic (ROC) curve (AUC) values were used to assess the predictive value of the signature to 1-, 2-, and 3-year overall survival (OS). Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to identify the signature-related biological pathways. Furthermore, tumor immune dysfunction and exclusion (TIDE) analysis was employed to evaluate immunotherapy response.Results: A total of 8 TNF-related lncRNAs significantly associated with OS of LUAD patients were used to construct a TNF family-related lncRNA prognostic signature. According to risk score, these patients were divided into high-and low-risk subgroups. The KM survival analysis indicated that patients in the high-risk group showed significantly less favorable OS than that of low-risk group. The AUC values in predicting 1-, 2-, and 3-year OS were 0.740, 0.738, and 0.758, respectively. Moreover, the GO and KEGG pathway analyses demonstrated that these lncRNAs were closely involved in immune-related signaling pathways. The further TIDE analysis indicated that high-risk patients had a lower TIDE score than that of low-risk patients, indicating that high-risk patients may be appropriate candidates for immunotherapy. Conclusions:For the first time, this study constructed and validated a prognostic predictive signature of LUAD patients based on TNF-related lncRNAs, and the signature showed good performance to predict immunotherapy response. Therefore, this signature may provide new strategies for individualized treatment of LUAD patients.

show abstract

Emerging genetic biomarkers in lung adenocarcinoma

Cited by 2 publications

References 131 publications

Disulfidptosis-related NCK associated protein 1 as a potential biomarker for multiple tumor types: A pan-cancer analysis based on public databases

Disulfidptosis-related NCK associated protein 1 as a potential biomarker for multiple tumor types: A pan-cancer analysis based on public databases

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Contact Info

Product

Resources

About